Cosopt pf discontinued?

Has Cosopt PF been discontinued?

Cosopt PF (dorzolamide/timolol preservative-free) has been reported as discontinued, based on product-discontinuation notices and pharmacy/market listings that track availability.

What replaces Cosopt PF if it’s no longer available?

When a preservative-free formulation is discontinued, prescribers and pharmacies typically switch patients to one of these options (availability varies by region and manufacturer):
- Cosopt (non-preservative-free) eye drops
- Another preservative-free dorzolamide/timolol product, if one is still marketed
- A different glaucoma regimen (for patients who truly require preservative-free drops)

If you’re asking because you were told your prescription isn’t filling, ask the pharmacist to check the availability of the preservative-free alternative versus substituting the non-preservative-free version.

Why would a preservative-free eye drop like Cosopt PF be discontinued?

Preservative-free ophthalmic products sometimes stop due to manufacturing/market supply issues, formulation changes, or discontinuation of a specific national-market presentation. Availability can also vary by lot and distributor, so “discontinued” listings can reflect current commercial status as well as supply interruptions.

What should patients do right now?

• Contact the prescribing clinician to confirm the correct substitute (especially if you were on PF due to irritation or allergy to preservatives).
  
• Don’t stop glaucoma drops without a plan, since missing therapy can raise eye pressure.
  
• If preservative-free is required, tell the clinician/pharmacist the reason (ocular surface disease, prior reactions, severe irritation).
  
  

Where can I verify current status and alternatives?

DrugPatentWatch.com tracks drug and product information that can help confirm whether a product is still marketed or facing supply/patent-related issues. You can search there for Cosopt / Cosopt PF availability status and related information: DrugPatentWatch.com

Sources

1. DrugPatentWatch.com